Previous 10 | Next 10 |
2023-03-07 12:39:41 ET Gainers: ThredUp ( TDUP ) +73% . WW International ( WW ) +49% . Unicycive ( UNCY ) +39% . Protagonist Therapeutics ( PTGX ) +32% . Bionomics ( BNOX ) +28% . Novo Integrated Sciences ( NVOS ) +25% ...
2023-03-07 11:28:43 ET Gainers: Unicycive ( UNCY ) +52% . Bionomics ( BNOX ) +49% . Novo Integrated Sciences ( NVOS ) +37% . Protagonist Therapeutics ( PTGX ) +34% . Allakos ( ALLK ) +22% . Losers: Cara ( CARA ) -28...
2023-03-07 08:27:38 ET Cara Therapeutics CARA -28% on Q4 results. Appreciate Holdings ( SFR ) -16% . Tremor International TRMR -12% on Q4 results. THOR Industries THO -11% on Q2 results. Ambrx Biopharma ( AMAM ) -9% . Avalon ...
2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...
Company to Transfer Stock Exchange Listing from NYSE to Nasdaq Ticker symbol will remain “AMAM” Ambrx Biopharma Inc. (NYSE: AMAM ) (“Ambrx” or “the Company”) today announced that it will voluntarily transfer its stock exchange listin...
Summary Ambrx shares faced delisting from the Nasdaq after a difficult 2022 that saw shares trade >$0.5. The company IPOd in June 2021, issuing 7m ADR shares and raising $126m. Ambrx had high hopes that lead candidate ARX788 could secure accelerated approval in HER+ breast cancer...
Performance Shipping ( PSHG ) -43% . Novavax ( NVAX ) -28% on Q4 earnings release . Tupperware Brands TUP -25% after posting preliminary results . First Horizon ( FHN ) -23% as TD says it won't receive regulatory OK in time for May close . M...
An interim analysis for ACE-Breast-02, a Phase 3 breast cancer clinical trial conducted by Ambrx Biopharma's ( NYSE: AMAM ) partner NovoCodex Biopharmaceuticals has met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a gr...
Interim analysis of the ACE-Breast-02 study being conducted by Ambrx’s partner, NovoCodex Biopharmaceuticals, was completed by the Independent Data Monitoring Committee (IDMC) The pivotal Phase 3 ACE-Breast-02 study met its pre-specified interim primary efficacy endpoint with stati...
TEGNA TGNA -22% after FCC orders hearing for Standard General sale . Mount Rainier Acquisition RNER -15% on FY earnings release . Ready Capital RC -12% on Q4 earnings release . Atlas Lithium ( ATLX ) -11% . Movella ( MVLA ) -10% . Ambrx ...
News, Short Squeeze, Breakout and More Instantly...
Ambrx Biopharma Inc. American Depositary Shares (each representing seven) Company Name:
AMAM Stock Symbol:
NYSE Market:
Ambrx Biopharma Inc. American Depositary Shares (each representing seven) Website:
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
Ambrx Biopharma Inc. (AMAM) is expected to report $-0.41 for Q4 2023
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Spe...